

Best Available Copy



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

0 080 779

A1

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 82201507.9

(61) Int.Cl.: C 07 D 223/16

(22) Date of filing: 29.11.82

A 61 K 31/55
 //C07C87/28, C07C91/06,
 C07C103/78

(30) Priority: 27.11.81 US 325249
 14.07.82 US 398015
 08.10.82 EP 82305361

(21) Applicant: SMITHKLINE BECKMAN CORPORATION
 1 Franklin Plaza
 Philadelphia Pennsylvania 19101(US)

(43) Date of publication of application:
 08.06.83 Bulletin 83/23

(22) Inventor: DeMarinis, Robert Michael
 104 Cedarbrook Road
 Ardmore Pennsylvania 19003(US)

(54) Designated Contracting States:
 AT BE CH DE FR GB IT LI LU NL SE

(22) Inventor: Hlaibis, Jacob Paul
 2107 Mount Vernon Street
 Philadelphia Pennsylvania 19130(US)

(22) Inventor: Matthews, William David
 812 Happy Creek Lane
 West Chester Pennsylvania 19380(US)

(22) Representative: Johnston, Walter Paul et al.,
 Patent Department SMITH KLINE & FRENCH
 LABORATORIES LTD Mundells
 Welwyn Garden City Hertfordshire AL7 1EY(GB)

(54) 3-Benzazepines as alpha₂-agonists.

(54) A pharmaceutical composition for producing alpha₂-agonism comprising a pharmaceutically acceptable carrier and a 3-benzazepine compound of the formula:



In which

R is a lower alkyl having from 1 to 3 carbon atoms or ethyl;
 and

X is halogen; or a pharmaceutically acceptable acid addition salt thereof.

EP 0 080 779 A1

3-Benzazepines as Alpha-2 Antagonists

5 This invention relates to pharmaceutical compositions and a method of producing alpha2 antagonism by employing certain N-substituted 2,3,4,5-tetrahydro-1H-3-benzazepines.

10 The pharmaceutical compositions and methods of this invention produce alpha2 antagonism, a pharmacological action which is associated with the reduction of intraocular pressure and a broad spectrum of cardiovascular activity. For example, the compounds of this invention may be used for treating congestive heart 15 failure, angina pectoris, and thrombosis.

20 Advantageously, the compounds also produce a reduction in blood pressure and are therefore useful as antihypertensive agents. This invention also relates to a method of producing antihypertensive activity by administering these compounds.

25 Reduction of intraocular pressure is of significant importance in the treatment of glaucoma which is a disease of the eye characterized by increased intraocular pressure. Glaucoma is a leading cause of blindness in people over forty. In poorly controlled glaucoma, the intraocular pressure is persistently increased and there is a progressive retinal and optic nerve degeneration. 30 If untreated, a red painful eye may occur accompanied by reduced vision and eventually blindness.

35 The three agents most commonly used in glaucoma therapy are pilocarpine, timolol or epinephrine. Pilocarpine causes miosis and spasm of the ciliary muscle which produces blurred vision and myopia. Epinephrine

- dilates the pupil and blurs the vision as well as induces hyperemia, macular edema and allergic reactions in the eye. Moreover, systemic absorption of epinephrine after ocular instillation has produced cardiac arrhythmias.
- 5 Timolol has few notable ocular side effects but systemic actions of the drug are a problem. Bradycardia, syncope, exacerbation of borderline congestive heart failure and bronchospasm have all been reported after topical timolol administration.
- 10 A still further disadvantage associated with epinephrine is that it is unstable to both air and light and subject to chemical attack by many agents that are conventionally used in pharmaceutical preparations.
- 15 Attempts made to overcome these disadvantages usually resulted in compositions that were irritating to the body tissues or formed biologically inactive derivatives thereof.
- 20 It is therefore an object of this invention to produce ophthalmic compositions and methods for lowering intraocular pressure which lack direct effect on pupil size, have no effect on heart rate or blood pressure in normotensive animals, and minimal local or systemic adverse effects upon instillation into the eye.
- 25

The novel compositions and methods of using them described hereafter have been found unexpectedly to reduce intraocular pressure without the undesirable side effects and disadvantages of the prior art agents noted above.

Description of Prior Art

- 35 United States Patents 4,210,749 and 4,233,217 disclose a broad class of benzazepines being useful as

-3-


analgesics, antihistaminics and narcotic antagonists. However, there is no specific disclosure of the compounds of Formula I. Moreover, there is no suggestion in these patents that the compounds of Formula I would be useful 5 as alpha₂ antagonists. One specific compound of Formula I, 6-chloro-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine has been disclosed as a chemical intermediate in United States Patent 4,265,890. There is no suggestion in this patent that the compound has any useful biological 10 activity. United States Patents 3,716,639 and 3,752,892 disclose 7-chloro and 6-chloro-2,3,4,5-tetrahydro-1H-3-benzazepines as anorexigenic agents.

15 None of the above known art discloses the biological activities of the claimed compositions and methods.

Description of Invention

20 The N-substituted 2,3,4,5-tetrahydro-1H-3-benzazepine compounds which are the active ingredients of the pharmaceutical compositions of this invention are represented by the following formula:

Formula I



30

in which:

35 R is lower alkyl of from 1 to 3 carbon atoms or allyl;
and

-4-


X is halogen such as chloro, bromo or fluoro, and a pharmaceutically acceptable acid addition salt thereof.

5 A particularly preferred compound in the pharmaceutical compositions and methods of this invention is a compound of Formula I in which R is methyl and X is chloro being the compound 6-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine.


10

The above compounds of Formula I which are the active ingredients in the compositions and method for producing alpha2 antagonism are prepared by synthetic methods familiar to the art. The most advantageous 15 procedure is as follows:


20



25



30



35

The terms X and R are as defined above.

According to the above procedure, a halophenyl acetic acid is treated with thionyl chloride followed by an appropriate amino alcohol. The resultant amide is reduced by any well known agent such as, for example,
5 borane. The resultant amino alcohol is then converted to the corresponding halide, such as chloride or bromide, and cyclized under Friedel-Crafts conditions. The cyclization step is carried out using Lewis acids, such as, for example, aluminum chloride, aluminum bromide,
10 titanium chloride and antimony chloride. Advantageously the cyclization is carried out in a melt of aluminum chloride and ammonium chloride at elevated temperatures.

The compounds of Formula I may also be prepared by reacting a 3-benzazepine compound in which R is hydrogen with an alkylating or acylating reagent which will replace the hydrogen with the desired R group. Such reagents include compounds of the formula RX and RCOY wherein R is as defined above for Formula I and Y is
20 halogen, such as chloro or bromo. Other reagents could include aldehydes or ketones.

When an aldehyde or ketone is used as the reagent it is followed by reductive alkylation. The reduction can be accomplished catalytically, such as with hydrogen and platinum, or chemically, such as with sodium borohydride or sodium cyanoborohydride.

When the reagent of the formula RCOY is employed,
30 the carbonyl moiety is subsequently reduced with, for example, lithium aluminum hydride.

The pharmaceutically acceptable acid addition salts having the utility of the free bases of Formula I,
35 prepared by methods well known to the art, are formed with both inorganic or organic acids, for example:

According to the above procedure, a halophenyl acetic acid is treated with thionyl chloride followed by an appropriate amino alcohol. The resultant amide is reduced by any well known agent such as, for example, 5 borane. The resultant amino alcohol is then converted to the corresponding halide, such as chloride or bromide, and cyclized under Friedel-Crafts conditions. The cyclization step is carried out using Lewis acids, such as, for example, aluminum chloride, aluminum bromide, 10 titanium chloride and antimony chloride. Advantageously the cyclization is carried out in a melt of aluminum chloride and ammonium chloride at elevated temperatures.

The compounds of Formula I may also be prepared by 15 reacting a 3-benzazepine compound in which R is hydrogen with an alkylating or acylating reagent which will replace the hydrogen with the desired R group. Such reagents include compounds of the formula RX and RCOY wherein R is as defined above for Formula I and Y is 20 halogen, such as chloro or bromo. Other reagents could include aldehydes or ketones.

When an aldehyde or ketone is used as the reagent it is followed by reductive alkylation. The reduction can 25 be accomplished catalytically, such as with hydrogen and platinum, or chemically, such as with sodium borohydride or sodium cyanoborohydride.

When the reagent of the formula RCOY is employed, 30 the carbonyl moiety is subsequently reduced with, for example, lithium aluminum hydride.

The pharmaceutically acceptable acid addition salts having the utility of the free bases of Formula I, 35 prepared by methods well known to the art, are formed with both inorganic or organic acids, for example:

maleic, fumaric, benzoic, ascorbic, pamoic, succinic,
bis- methylenesalicylic, methanesulfonic, ethanedi-
sulfonic, acetic, oxalic, propionic, tartaric, salicylic,
citric, gluconic, aspartic, stearic, palmitic, itaconic,
5 glycolic, p-aminobenzoic, glutamic, benzenesulfonic,
hydrochloric, hydrobromic, sulfuric, cyclohexylsulfamic,
phosphoric and nitric acids.

The activity of the compounds of Formula I is
10 demonstrated in vitro by determining the prejunctional
alpha2 antagonist activity using the isolated superfused
guinea pig left atrium. Briefly, the heart is removed
from a pentobarbital-anesthetized male guinea pig. The
left atrium is removed, dissected free of extraneous
15 tissue and mounted in a 2 ml. superfusion chamber. The
tissue is paced at 60 pulse/minute and the sympathetic
nerves excited at 6 minute intervals by field stimulation.
The response to nerve stimulation is measured as the
difference in contractile force between the basal
20 contraction and peak contraction following a nerve stimu-
lation. A concentration-response curve for clonidine
(alpha2 agonist) is prepared by administering an
increasing concentration of clonidine following each
successive stimulation. The tissue is then superfused
25 with the alpha2 antagonist to be tested for thirty
minutes and the clonidine concentration-effect curve was
repeated in the presence of antagonist. The receptor
dissociation constant of the antagonist (KB) is defined
as the antagonist concentration required to shift the log
30 concentration-response curve of the agonist to the right
by a factor of 2.

5 Selectivity for the alpha2 vis-a-vis the alphal-adrenoceptor is determined by comparing the KB obtained as described above with the KB on the alphal receptor determined in the rabbit ear artery segment as an antagonist of the constrictor response induced by norepinephrine. (Hieble and Pendleton, Arch. Pharmacol., 309, 217-224 (1979)).

10 A preferred compound of this invention is 6-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine which has a KB value in the isolated perfused guinea pig left atrium of 13 nM.

15 When substitution is present at the 7-position of the benz-ring, a dramatic reduction in activity results. For example, the 7-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine has a KB value of 150 nM, i.e., about one tenth the alpha2 antagonist activity of the 6-chloro derivative. Further, when a substituent such 20 as amino is present at the 6-position of the benz-ring, or the 6 and 7 positions are fused to a cyclopentane ring, the compounds are completely inactive as alpha2 antagonists.

25 The antihypertensive activity of the compounds of this invention is demonstrated in vivo as follows:

Male rats (300-450 g.) are anesthetized with sodium brevital and the femoral vein and artery are cannulated. Cannulas are run intradermally so as to be externalized in the dorso-sacral area of either side and kept in place by wound clips. The rats are allowed to regain consciousness after being placed in a small animal restrainer. The arterial cannula is connected to a pressure transducer for constant blood pressure and heart rate monitoring. Drugs are administered either orally via gavage or i.v. via the femoral vein cannula at a rate of 0.06 ml./minute.

The above test is conducted on both normotensive and hypertensive rats. DOCA Salt hypertensive rats are prepared from male uninephrectomized Sprague-Dawley rats. The rats, approximately six weeks of age, are lightly anesthetized with ether and subcutaneously implanted with a 25 mg. deoxycorticosterone acetate pellet in the left dorso-sacral area. Six days later a second pellet is implanted in the right dorso-sacral area. These rats are fed a normal laboratory diet, but are given 1½ saline solution to drink in place of water. The rats are kept on the saline drinking water for 22-24 days.

The following table sets forth the effect of 6-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine on blood pressure after i.v. administration to both normotensive and hypertensive rats.

Table 1

Type of Rats	Diastolic Blood Pressure		
	PreDrug	Decrease BP (MMHg)	0.5 mg/Kg I.V.
5 Normotensive (control) (Sprague-Dawley) (n = 4)	95 ± 7 MMHg	6 ± 2	13 ± 1
10 DOCA Salt Hyper- tensive (n = 4)	135 ± 5 MMHg	27 ± 3	33 ± 4
15 Normotensive (control) (Wistar-Kyoto) (n = 4)	115 ± 3 MMHg	7 ± 2	10 ± 2
Spontaneously Hypertensive (n = 7)	167 ± 3 MMHg	33 ± 7	46 ± 2

20

n = Number of rats

The data in Table 1 demonstrate that while 6-chloro-
2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine has little
25 effect on diastolic blood pressure in normotensive rats,
it produced a marked drop in diastolic blood pressure in
both DOCA Salt and spontaneously hypertensive rats.
Moreover, comparison of the 0.5 mg./kg. and 1.0 mg./kg.
doses shows that the antihypertensive effect is dose-
30 related.

The effect of the oral administration of 6-chloro-
2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine on blood

pressure in the DOCA-salt hypertensive rat was also determined. Table 2 below sets forth the results of this test.

5

Table 2

	Dose (PO)	<u>Mean Arterial Pressure</u>		Δ BP (MM Hg)
		Pre-Drug	Post-Drug	
10	2 mg/kg	148 \pm 11	131 \pm 12	17 \pm 3
15	5 mg/kg	160 \pm 7	127 \pm 5	34 \pm 4
	10 mg/kg	167 \pm 8	99 \pm 4	68 \pm 8

In addition, for cardiovascular use, the compositions of this invention may be combined with thiazide diuretics such as hydrochlorothiazide, triamterene, or calcium channel blockers such as Verapamil or Nifedipine, or β -adrenergic blockers such as propranolol. The amount of the substituted 3-benzazepines in the compositions of this invention would be in the ranges noted above combined with from about 2 mg. to about 250 mg. of the thiazide component. When combined with triamterene, from about 5 mg. to about 250 mg. of triamterene would be present. When a calcium channel blocker is employed in the compositions of this invention, from about 1 mg. to about 500 mg. would be employed.

A further activity of the compounds of this invention is demonstrated by their ability to reduce intraocular pressure. The measurement of intraocular pressure depends on subjecting the eye to a force that indents or

flattens it. Either the effect of a particular force or the force for a given effect is measured. The specific procedure employed for the compounds of this invention is a normal rabbit intraocular pressure determination. A
5 solution of 0.5% proparacaine hydrochloride diluted 1:10 with physiological saline is instilled into the eye of a rabbit. The lids are gently massaged over the cornea to insure good distribution of the solution. The eye is exposed by separating the lids and the tip of a probe is
10 slowly placed on the cornea at the point where the curvature of the cornea is the greatest, i.e., on the optic axis. Employing an Alcon Applanation Pneumatonomograph, the intraocular pressure is determined in each eye until a stable reading is obtained. West, C., Capella,
15 J. and Kaufman, H., Am. J. Ophthalmol. 74:505 (1972).

Nine rabbits are used in each study, three animals for each dose in most circumstances. An initial, $t=0$, intraocular determination is made in both eyes.
20 Immediately following the initial reading, the formulations to be tested, comprising concentrations of 0.01 to 10% of active ingredient, are instilled and pressure readings are taken at 0.5, 1, 2, 3, 4, and 6 hours post-instillation. The intraocular pressure is determined
25 from the value recorded on the pneumotonograph chart paper. A mean intraocular pressure value is calculated at each time point. A preferred compound of this invention, 6-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine, decreases intraocular pressure at one hour by 3.5 mm. of mercury relative to the untreated eye.

When the chloro was placed on the 7-position of the benzazepine nucleus and the compound was administered at the same doses, there was no lowering of intraocular pressure.
35

In summary, the structures of the compounds of this invention are specifically identified by having the halo at the 6-position of the benzazepine nucleus. As noted from the results of the test for alpha2 antagonism and the lowering of intraocular pressure, this is a critical feature of the compounds of this invention in order to obtain the desired biological activity. It was also unexpectedly discovered that when the preferred compound, 6-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine, was given systemically and the above procedure was followed, intraocular pressure was lowered with no significant effect on systemic blood pressure. For example, when 0.5 mg./kg. of the compound was infused in the ear vein of conscious normotensive rabbits, the compound decreased intraocular pressure at one hour by between 4 and 5 mm. of mercury.

The pharmaceutical compositions used to carry out the method of producing alpha2 antagonism and anti-hypertensive activity comprise a pharmaceutical carrier and, as the active ingredient, a benzazepine compound of Formula I. The active ingredient will be present in the compositions in an effective amount to produce alpha2 antagonism and antihypertensive activity.

Preferably, the compositions contain the active ingredient of Formula I in an amount of from about 25 mg. to about 500 mg., advantageously from about 50 mg. to about 250 mg., per dosage unit.

The pharmaceutical carrier may be for example a solid or a liquid. Exemplary of solid carriers are lactose, magnesium stearate, terra alba, sucrose, talc, stearic acid, gelatin, agar, pectin or acacia. The amount of solid carrier will vary widely but preferably will be from about 25 mg. to about 1 gm. Exemplary of

5 liquid carriers are syrup, peanut oil, olive oil, sesame oil, propylene glycol, polyethylene glycol (mol. wt. 200-400) and water. The carrier or diluent may include a time delay material well known to the art such as, for example, glyceryl monostearate or glyceryl distearate alone or with a wax.

10 A wide variety of pharmaceutical forms can be employed, for example, the preparation may take the form tablets, capsules, powders, troches, lozenges, syrups, emulsions, sterile injectable liquids or liquid suspensions or solutions.

15 The pharmaceutical compositions are prepared by conventional techniques involving procedures such as mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation.

20 Preferably, the compounds of Formula I are administered in conventional dosage unit forms prepared by combining an appropriate dose of the compound with standard pharmaceutical carriers.

25 Preferably, the active ingredient of Formula I will be administered in a daily dosage regimen of from about 100 mg. to about 1000 mg., most preferably from about 200 mg. to about 500 mg. Advantageously, equal doses will be administered preferably two to four times per day.

30 The pharmaceutical compositions of this invention which reduce intraocular pressure comprise a pharmaceutical carrier, preferably an ophthalmic vehicle, and as the active ingredient an N-substituted 2,3,4,5-tetrahydro-1H-3-benzazepine of Formula I. The active 35 ingredient will be present in the compositions of this invention in an effective amount to reduce intraocular

pressure. Preferably, the compositions of this invention contain from about 0.01% to about 5.0% of the active ingredient of Formula I, advantageously, from about 0.03% to about 3.0%.

5

The ophthalmic vehicle or carrier may be, for example, a liquid or solid. Exemplary of liquid ophthalmic carriers include standard 1.9% isotonic boric acid, 0.9% sodium chloride, or sodium borate solutions. 10 Further, conventional phosphate buffer solutions such as the Sorenson phosphate buffer having a pH of 6.8 may be employed as the carrier. Exemplary of solid ophthalmic carriers may be typical ointment bases such as petrolatum.

15

The compositions of the present invention can be administered topically to the eye in dosage unit forms, such as, for example, ophthalmic solutions, ointments, creams, gels, or dispersions. When controlled release of the compound is desired, it may alternatively be incorporated into polymeric ocular insert systems which are well known to the art such as, for example, U.S. Patent No. 4,052,505.

25

The ophthalmic solutions are sterile and can contain in addition to the compound of Formula I anti-microbial agents. Exemplary of such agents are the quaternary ammonium germicides such as benzalkonium chloride, benzethonium chloride or cetylpyridium chloride. Other such agents that can be employed are chlorobutanol or phenylmercuric nitrate. If antioxidants are required, sodium sulfite, sodium ascorbate or other ophthalmologically acceptable antioxidants known to the art such as oxime sulfate may be used.

35

The benzazepine compound is preferably administered in ophthalmological dosage unit forms prepared by

-15-

5 combining an appropriate dose of the compound with the above noted ophthalmological carriers. Preferably the ophthalmic dosage form is applied from two to four times daily. When an ophthalmic solution is employed one to five drops may be administered two to four times a day.

When the administration is carried out as described above, alpha₂ antagonism, antihypertensive activity and a lowering of intraocular pressure is produced.

10

The following Examples are not limiting but are illustrative of the compounds of this invention and processes for their preparation. The temperatures are in degrees Centigrade.

15

Example 1

A mixture of 125 g. (0.73 mol) of O-chlorophenyl-acetic acid, 155 g. (1.3 mol) of thionyl chloride and 2-3
5 drops of dimethylformamide in 1500 ml. of toluene was stirred at room temperature for three hours. The toluene was evaporated under reduced pressure to give an oil which was dissolved in 200 ml. of methylene chloride. This was added dropwise to a solution of 165 g. (2.2 mol)
10 of N-methylamino ethanol in 1 liter of methylene chloride. After addition was complete, the solution was stirred at room temperature for three hours. The organic solution was washed with water, dilute hydrochloric acid and saturated sodium chloride, dried over magnesium sulfate, filtered and evaporated to give 2-chloro-N-(2-hydroxyethyl)-N-methylbenzeneacetamide as a crystalline solid, m.p. 77°.

To 400 ml. of a 1 mol solution of borane in tetrahydrofuran was added dropwise a solution of 43 g. of the above amide in 350 ml. of tetrahydrofuran at a rate sufficient to maintain a gentle reflux. After addition was complete, the solution was refluxed for two hours, cooled in an ice bath and treated carefully with dilute hydrochloric acid to destroy excess borane. The majority of the solvent was removed under vacuum and the residue heated on a steam bath for one hour. The mixture was diluted with 300 ml. of water and extracted with ether. The aqueous layer was made basic with 40% sodium hydroxide and extracted with ether. The combined basic extracts were washed with water and saturated sodium chloride, dried and evaporated to give 2-[{2-(2-chlorophenyl)ethyl}-methylamino]ethanol.

35 A suspension of 36 g. (0.173 mol) of phosphorous pentachloride in 300 ml. of methylene chloride was

treated dropwise with a solution of 37 g. (0.173 mol) of the 2-[{2-(2-chlorophenyl)ethyl}methylamino]ethanol in 150 ml. of methylene chloride. After addition was complete, the mixture was refluxed overnight, evaporated to dryness and partitioned between dilute hydrochloric acid and ether. The aqueous layer was made basic with 10% sodium hydroxide and extracted well with ether. The ether extracts were washed with water and saturated sodium chloride, dried over magnesium sulfate and filtered.

5 Addition of a saturated solution of ethereal hydrogen chloride gave a solid precipitate which was removed by filtration, washed with ether and dried to give 2-chloro-N-(2-chloroethyl)-N-methylbenzene ethanamine hydrochloride, m.p. 110°.

10 To a mixture of 41.5 g. (0.155 mol) of the above chloro ethanamine hydrochloride and 6.26 g. (0.117 mol) of ammonium chloride was added 41 g. of anhydrous aluminum chloride. The reaction became homogenous, melted and exothermed. It was placed in an oil bath which had been heated to 175° and stirred for thirty minutes. An additional 20 g. of aluminum chloride was added and the mixture heated for another thirty minutes. A final 41 g. portion of aluminum chloride was added and the reaction heated for twenty hours. It was cooled to 140° and poured into 3 l. of ice water containing 300 ml. of concentrated hydrochloric acid and stirred for fifteen minutes. Sixty grams of sodium potassium tartrate was added and stirred until solution was effected. It was made basic with 40% sodium hydroxide, extracted twice with ether and the combined extracts washed with water, and saturated sodium chloride, dried and reduced in volume by half. Addition of a solution of saturated ethereal hydrogen chloride gave a solid precipitate which was collected, washed with ether and dried to give a white solid. Crystallization from methanol-ethyl acetate gave

15 30 35

-18-

6-chloro-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride, m.p. 268-270°.

Example 2

- 5 A stirred solution of 1.2 g. of 6-chloro-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine in 30 ml. of toluene was treated at 50° by dropwise addition with a solution of 0.7 g. cyanogen bromide in 25 ml. of toluene.
10 Following the addition, the mixture was stirred and heated at 50° for one hour. A stream of nitrogen was passed over the surface of the solution during the reaction. The mixture was cooled, filtered and the filtrate concentrated in vacuo to yield 6-chloro-3-cyano-2,3,4,5-tetrahydro-1H-3-benzazepine melting at 81-82° from hexane-ether solution.

20 The 6-chloro-3-cyano-2,3,4,5-tetrahydro-1H-3-benzazepine was refluxed for 19 hours in a mixture of 30 ml. of glacial acetic acid and 30 ml. of 6N hydrochloric acid. The mixture was concentrated in vacuo to yield 6-chloro-2,3,4,5-tetrahydro-1H-3-benzazepine as the hydrochloride salt of m.p. 214-215° from ethanol. This salt in turn gave the base 6-chloro-2,3,4,5-tetrahydro-1H-3-benzazepine on treatment with dilute sodium hydroxide solution.

Example 3

- 30 A mixture of 0.52 g. of 6-chloro-2,3,4,5-tetrahydro-1H-3-benzazepine, 0.34 g. of allyl bromide, 0.6 g. of potassium carbonate and 20 ml. of 90% ethanol was stirred at room temperature for 17 hours. The mixture was filtered and the filtrate concentrated in vacuo. The residue was extracted with 35 ml. of ether and the etheral extract treated with isoproponolic hydrogen

chloride to precipitate 3-allyl-6-chloro-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride. Recrystallization of this salt from absolute ethanol gave 3-allyl-6-chloro-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride having
5 a melting point of 248-249°.

Example 4

A solution of 1.5 g. of 6-chloro-2,3,4,5-tetrahydro-
10 1H-3-benzazepine, 2.0 g. of acetic anhydride and 20 ml. of pyridine was stirred at room temperature for 3 hours. The mixture was concentrated in vacuo and the residue washed with 3N hydrochloric acid, then water, to yield 3-acetyl-6-chloro-2,3,4,5-tetrahydro-1H-3-benzazepine
15 melting at 64-66°. This amide was reduced in ether with a 50% excess of lithium aluminum hydride at reflux for 6 hours. Upon decomposition of excess reducing agent, the reaction mixture was filtered and the ethereal filtrate dried over magnesium sulfate. The filtrate was treated
20 with ethereal hydrogen chloride solution to precipitate 6-chloro-3-ethyl-2,3,4,5-tetrahydro-1H-3-benzazepine as the hydrochloride salt which melted at 274-275° from absolute alcohol.

25 Example 5

Following the procedure of Example 1 and substituting 2-[(2-(2-chlorophenyl)ethyl)ethylamino]-ethanol and 2-[(2-(2-chlorophenyl)ethyl)allylamino]-ethanol for 2-[(2-(2-chlorophenyl)ethyl)methylamino]-ethanol yields the following respective products: 6-chloro-3-ethyl-2,3,4,5-tetrahydro-1H-3-benzazepine and 6-chloro-3-allyl-2,3,4,5-tetrahydro-1H-3-benzazepine.

-20-

Example 6

	<u>Ingredients</u>	<u>% W/W</u>
5	6-Chloro-2,3,4,5-Tetrahydro-3-Methyl-1H-3-Benzazepine Hydrochloride	2.5 g.
	Benzalkonium Chloride	0.02 g.
10	Sodium Bisulfite	0.10 g.
	Sterile Sodium Chloride Solution (0.9%) USP	qs 100 ml.

15 The ingredients are dissolved in the sodium chloride solution. The solution is sterilized by filtration and aseptically packaged.

20 Two drops are instilled in the eye three times a day.

Example 7

	<u>Ingredients</u>	<u>% W/W</u>
25	6-Chloro-2,3,4,5-Tetrahydro-3-Methyl-1H-3-Benzazepine	1.0 g.
	Purified White Petrolatum, U.S.P.	qs 100.0 g.

30 Under aseptic conditions, the benzazepine is thoroughly incorporated in the petrolatum and packaged.

The ointment is applied topically to the eye four times a day.

0080779

SKB 14094/126

-21-

Example 8

	<u>Ingredient</u>	<u>Amounts</u>
5	6-Chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine hydrochloride	150 mg.
	Lactose	350 mg.
10	The ingredients are mixed and filled into a hard gelatin capsule.	
One capsule is administered four times a day.		

15 Example 9

	<u>Ingredients</u>	<u>Amounts</u>
20	6-Chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine hydrochloride	200 mg.
	Calcium sulfate dihydrate	150 mg.
25	Sucrose	25 mg.
	Starch	15 mg.
	Talc	5 mg.
30	Stearic Acid	3 mg.

The calcium sulfate dihydrate, sucrose and the benzazepine are thoroughly mixed and granulated with 10% gelatin solution. The wet granules are screened, dried

-22-

and then mixed with the starch, talc and stearic acid,
screened and compressed into a tablet.

One tablet is administered three times a day.

5 Example 10

	<u>Ingredient</u>	<u>Amounts</u>
10	6-Chloro-2,3,4,5-tetrahydro- 1H-3-benzazepine hydrochloride	500 mg.
15	Lactose	50 mg.


The ingredients are mixed and filled into a hard
gelatin capsule.

One capsule is administered two times a day.

Claims:

- 5 1. A pharmaceutical composition for producing
alpha2 antagonism comprising a pharmaceutically
acceptable carrier and a 3-benzazepine compound of the
formula:

10



15

in which:

20

R is lower alkyl having from 1 to 3 carbon atoms or
allyl; and

X is halogen; or a pharmaceutically acceptable acid
addition salt thereof.

25

2. The pharmaceutical composition of Claim 1 in
which R is methyl and X is chloro being the compound
6-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine.

30

3. The composition of Claim 2 in which the
3-benzazepine is in the form of its hydrochloride salt.

35


4. A pharmaceutical composition for reducing
intraocular pressure comprising a pharmaceutically
acceptable ophthalmic carrier and a 3-benzazepine compound
of Claim 1.

-24-

5. A pharmaceutical composition for producing anti-hypertensive activity comprising a pharmaceutically acceptable carrier and a 3-benzazepine compound of Claim 1.

6. A chemical compound for use as an alpha₂ antagonist of the formula:

10



15

in which:

20 R is lower alkyl having from 1 to 3 carbon atoms or allyl; and

25 X is halogen; or a pharmaceutically acceptable acid addition salt thereof.

7. The compound of Claim 6 in which R is methyl and X is chloro being the compound 6-chloro-2,,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine.

30 8. The compound of Claim 7 in the form of its hydrochloride salt.

0080779

SKB 14094/126

-25-

**9. A chemical compound for use in lowering
intraocular pressure having the formula of Claim 6.**

**10. A chemical compound for producing
5 antihypertensive activity having the formula of Claim 6.**


-2b-

Claims: (Austria)

1. The process for preparing a 3-benzazepine compound of the formula:

5

10




in which:

15 R is lower alkyl having from 1 to 3 carbon atoms or allyl; and

X is halogen, or a pharmaceutically acceptable acid addition salt thereof, which comprises:

20 (a) cyclizing a compound of the formula:

25




in which:

30 R is lower alkyl of from 1 to 3 carbon atoms or allyl, X is halogen, and Z is chloro or bromo; or

-23-

(b) reacting a compound of the formula:



in which X is halogen with:

10

(1) an alkylating reagent of the formula RY in which R is lower alkyl of from 1 to 3 carbon atoms or allyl, and Y is a reactive halogen, or

15

(2) an acylating reagent of the formula RCOY wherein R is methyl, ethyl, vinyl or methoxy and Y is as defined above followed by reduction of the acylated compound; and optionally forming a pharmaceutically acceptable acid addition salt of the 3-benzazepine product.

20

2. The process of Claim 1 in which R is methyl and X is chloro resulting in the product 6-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine.

25

3. The process of Claim 2 in which the product is reacted with hydrochloric acid to form the hydrochloride salt.

30

4. The process of Claim 1 in which the cyclization is accomplished in a melt of aluminum chloride and ammonium chloride at an elevated temperature.

0080779

European Patent
Office

EUROPEAN SEARCH REPORT

Application number

EP 82 20 1507

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.)
X	--- GB-A-1 268 243 (WALLACE & TIERNAN) *Complete document; especially claims*	1,4-6 9,10	C 07 D 223/16 A 61 K 31/55 C 07 C 87/28 C 07 C 91/06 C 07 C 103/78
X,D	--- US-A-4 210 749 (B.V.SHETTY) *Complete document; especially column 1, line 16 - column 2*	1,4-6 9,10	
Y,D	--- US-A-4 265 890 (K.G.HOLDEN) *Column 9, examples 8-9*	1,2,6 7	
Y,D	--- US-A-3 752 892 (K.HOEGERLE) *Complete document*	1,4-6 9,10	TECHNICAL FIELDS SEARCHED (Int. Cl.)
Y	--- US-A-2 520 264 (L.A.WALTER) *Complete document*	1,4-6 9,10	A 61 K 31/00 C 07 D 223/00

The present search report has been drawn up for all claims			
Place of search	Date of completion of the search	NUYTS	Examiner A.M.K.A.
THE HAGUE	15-02-1983		
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone	T : theory or principle underlying the invention		
Y : particularly relevant if combined with another document of the same category	E : earlier patent document, but published on or after the filing date		
A : technological background	D : document cited in the application		
O : non-written disclosure	L : document cited for other reasons		
P : intermediate document	& : member of the same patent family, corresponding document		

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.